"Genes, BRCA2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human chromosome 13 at locus 13q12.3. Mutations in this gene predispose humans to breast and ovarian cancer. It encodes a large, nuclear protein that is an essential component of DNA repair pathways, suppressing the formation of gross chromosomal rearrangements. (from Genes Dev 2000;14(11):1400-6)
| Descriptor ID |
D024522
|
| MeSH Number(s) |
G05.360.340.024.340.375.249.105 G05.360.340.024.340.415.400.105
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Genes, BRCA2".
Below are MeSH descriptors whose meaning is more specific than "Genes, BRCA2".
This graph shows the total number of publications written about "Genes, BRCA2" by people in this website by year, and whether "Genes, BRCA2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 2 | 0 | 2 |
| 2003 | 2 | 3 | 5 |
| 2006 | 2 | 0 | 2 |
| 2007 | 2 | 1 | 3 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 1 | 2 |
| 2013 | 0 | 1 | 1 |
| 2014 | 4 | 1 | 5 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 2 | 2 | 4 |
| 2018 | 1 | 0 | 1 |
| 2019 | 2 | 0 | 2 |
| 2020 | 1 | 1 | 2 |
| 2021 | 0 | 2 | 2 |
| 2025 | 0 | 1 | 1 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Genes, BRCA2" by people in Profiles.
-
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 01 06; 19(1):77-102.
-
The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer. PLoS One. 2012; 7(5):e37891.
-
Peritoneal washing cytology in patients with BRCA1 or BRCA2 mutations undergoing risk-reducing salpingo-oophorectomies: a 10-year experience and reappraisal of its clinical utility. Gynecol Oncol. 2012 Jun; 125(3):683-6.
-
The origin of ovarian cancer. BJOG. 2012 Jan; 119(2):134-6.
-
Communication of BRCA1 and BRCA2 genetic test results to health care providers following genetic testing at a tertiary care center. Fam Cancer. 2011 Dec; 10(4):673-9.
-
PARP inhibitors: the story is still unfolding. Oncology (Williston Park). 2011 Oct; 25(11):1028, 1030.
-
Genetic testing and cancer risk management recommendations by physicians for at-risk relatives. Genet Med. 2011 Feb; 13(2):148-54.
-
Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011 Mar 01; 17(5):1082-9.
-
Allelic imbalance in BRCA1 and BRCA2 gene expression and familial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2011 Jan; 20(1):50-6.
-
Personalizing therapy for ovarian cancer: BRCAness and beyond. J Clin Oncol. 2010 Aug 01; 28(22):3545-8.